|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Access Pharmaceuticals Inc., of Dallas, began the final Phase III study of OraDisc A, a mucoadhesive disc containing amlexanox for the treatment of canker sores. The study is expected to finish in the fourth quarter. OraDisc is a polymer disc technology that adheres to the disease site and slowly degrades, releasing the drug. The Phase III study will enroll 700 patients at 28 sites in the U.S. Separately, Access said it acquired from GlaxoSmithKline plc, of London, the patents and trademarks for amlexanox relating to the treatment of mucosal and skin disorders. Access gets U.S. marketing rights to amlexanox 5 percent paste, marketed for the treatment of canker sores under ...